Free RAC Postmarket Surveillance and Compliance Questions and Answers 1 — Questions and Answers
Question 1: A manufacturer becomes aware that a series of malfunctions with its infusion pump necessitates a nationwide field correction to prevent an unreasonable risk of substantial public harm. The company also has information reasonably suggesting these malfunctions may have contributed to a patient's death. According to 21 CFR 803, what is the mandatory reporting timeframe to the FDA for this event?
- 30 calendar days after becoming aware of the event.
- 10 working days after initiating the field correction.
- 5 working days after becoming aware that a reportable event requires remedial action. (Correct answer)
- Within 24 hours via a phone call to the district office.
Correct answer: 5 working days after becoming aware that a reportable event requires remedial action.
According to 21 CFR 803.53, a manufacturer must submit a 5-day report if they become aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. The need for a nationwide field correction to prevent such harm triggers this expedited reporting requirement.
Question 2: Under the EU Medical Device Regulation (MDR 2017/745), which of the following BEST describes the purpose of the Post-Market Surveillance Report (PMSR)?
- To provide a comprehensive summary of clinical investigation results for CE marking renewal.
- To fulfill marketing authorization requirements for the European Medicines Agency (EMA).
- To report all individual serious incidents to the competent authorities within 15 days.
- To summarize the results and conclusions of post-market surveillance data analysis primarily for Class I devices. (Correct answer)
Correct answer: To summarize the results and conclusions of post-market surveillance data analysis primarily for Class I devices.
The PMSR, as defined in Article 85 of the EU MDR, is required for Class I devices. It is a summary of the results and conclusions of the analyses of the post-market surveillance data. For higher-risk devices (Class IIa, IIb, and III), a more comprehensive Periodic Safety Update Report (PSUR) is required.
Question 3: A pharmaceutical company holds an approved New Drug Application (NDA). Which of the following is considered an "unexpected" adverse drug experience that would require an expedited 15-day "Alert Report" to the FDA?
- An adverse event that is listed in the current product labeling, but is now occurring with greater severity. (Correct answer)
- A serious adverse event that is already well-documented in the Investigator's Brochure from the clinical trial phase.
- A non-serious adverse event observed for the first time in a postmarketing study.
- A mild headache, which is listed as a common side effect in the product's core safety information.
Correct answer: An adverse event that is listed in the current product labeling, but is now occurring with greater severity.
Per 21 CFR 314.80(a), an "unexpected" adverse drug experience is one not listed in the current labeling. The definition explicitly includes events that may be related to an event in the labeling but differ because of greater severity or specificity. The Investigator's Brochure is not the same as the approved labeling, and non-serious or expected events do not trigger the 15-day reporting requirement.
Question 4: A medical device manufacturer identifies a software anomaly in its patient monitoring system that may, in rare circumstances, cause a temporary, 5-second data lag. This could theoretically lead to a brief delay in clinical intervention. The manufacturer initiates a voluntary correction. How would the FDA MOST likely classify this recall?
- Class I
- Class II (Correct answer)
- Class III
- Market Withdrawal
Correct answer: Class II
A Class II recall applies to situations where the use of a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The scenario describes a potential for temporary harm (delay in intervention), but serious harm is not a reasonable probability, fitting the Class II definition.
Question 5: The FDA has ordered a manufacturer to conduct a postmarket surveillance study under Section 522 of the FD&C Act for its permanently implantable device. This mandatory study is MOST likely intended to answer a specific question about the device's:
- marketing and promotional material accuracy.
- long-term performance and safety. (Correct answer)
- manufacturing cost-effectiveness.
- compliance with international standards.
Correct answer: long-term performance and safety.
Section 522 of the FD&C Act grants the FDA authority to require manufacturers to conduct postmarket surveillance to gather specific data on a device's long-term safety and effectiveness. These studies are ordered to address important public health questions that could not be fully answered with premarket data.
Question 6: A pharmaceutical company's call center receives a communication from a patient who states, "I felt dizzy after starting your new heart medication," but provides no further details. According to 21 CFR 211.198 (Complaint files), what is the MOST appropriate initial action?
- Immediately file a 15-day Alert Report to the FDA based on the information received.
- Wait for a healthcare professional to confirm the event before taking any action.
- Log the communication as a complaint and initiate a review or investigation according to written procedures. (Correct answer)
- Discard the communication as it lacks sufficient detail and confirmation to be a valid complaint.
Correct answer: Log the communication as a complaint and initiate a review or investigation according to written procedures.
Under 21 CFR 211.198, any written or oral communication that alleges deficiencies related to a drug product's quality, safety, or effectiveness is considered a complaint. The regulations require that all such complaints be documented and reviewed by the quality control unit according to established written procedures.
Free RAC Postmarket Surveillance and Compliance Questions and Answers 1
A manufacturer becomes aware that a series of malfunctions with its infusion pump necessitates a nationwide field correction to prevent an unreasonable risk of substantial public harm.
The company also has information reasonably suggesting these malfunctions may have contributed to a patient's death.
According to 21 CFR 803, what is the mandatory reporting timeframe to the FDA for this event?